山西仟源医药多位董高拟减持，合计不超42.66万股

Group 1 - The company Shanxi Qianyuan Pharmaceutical Group Co., Ltd. announced a pre-disclosure of share reduction by several directors and senior management [1] - The total shares planned to be reduced by the five individuals amount to no more than 426,600 shares, representing 0.1718% of the company's total share capital [1] - The individuals involved in the reduction include Yu Junxian, Gu Baoping, Yu Yingmin, He Yanjie, and Luo Kairui, with specific shareholdings and planned reductions detailed [1][2] Group 2 - The reasons for the share reduction include tax payments related to equity incentives and personal funding needs [2] - The shares to be reduced are sourced from various holdings, including pre-IPO shares, capital reserve conversions, and equity incentive grants [2] - The reduction price will be determined based on market conditions at the time of the sale, indicating some uncertainty in the execution of the plan [3] Group 3 - The share reduction plan does not violate any relevant laws or regulations and will not lead to changes in the company's control or governance structure [3] - The company will continue to monitor the progress of the share reduction plan and fulfill its information disclosure obligations as required [3]